Bora Pharmaceuticals (6472) Q4 2024 earnings summary

Executive summary

• Group revenues rose 35.5%–36% and net income increased 30%–31.5% year-over-year for 2024, driven by CDMO and commercial growth.

• CDMO revenues grew 30.3%, commercial revenues surged 84%, and major U.S. acquisitions (Upsher-Smith, Baltimore/Cangene, Pyros) expanded capacity and product portfolio.

• Launched new specialty products (Vigafyde, Potassium Chloride ER), maintained leading market share in key products, and completed a Taiwan Stock Exchange listing.

• Integration strategy included rationalizing low-margin products and shutting down inefficient facilities.

• Recognized with industry awards and new index inclusions (FTSE, MSCI, TPEX).

Financial highlights

• 2024 revenue reached NT$19,246 million, up 35%–36% year-over-year; net income was NT$3,939.0–4,040 million, up 30%–32%.

• Gross margin was 40%–42.8%, impacted by one-time acquisition and integration costs; operating margin declined due to higher OPEX.

• Basic EPS for 2024 was NT$38.69, up 28% year-over-year; diluted EPS was NT$35.82.

• Cash and cash equivalents increased to NT$5,829 million; total assets grew to NT$45,598.9 million.

• 41% payout ratio for 2024FY (36% cash, 5% stock).

Outlook and guidance

• 2025 growth expected from both CDMO and commercial segments, with realization of recent acquisitions, new product launches, and integration synergies.

• Maple Grove CDMO business to begin in March 2025; FlexPro injectable line in Baltimore to add 30% capacity in Q3 2025.

• Continued focus on high-margin generics, specialty, and rare disease products, especially Vigafyde.

• Ongoing rationalization of low-margin generics to improve margins.

• Investments in new growth areas in 2024 expected to contribute from 2025 onward.